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Abstract
Stress doses of hydrocortisone are known to have
immunomodulatory effects in patients with hyperdy-
namic septic shock. The prognosis correlates with the
presence and severity of septic encephalopathy. How-
ever, neurological evaluation is influenced by the use
of analgesia sedation during artificial ventilation. The
objective of this study was to demonstrate the effect
of stress doses of hydrocortisone during the initial
phase of human septic shock on the serum values of
the neurospecific protein S-100B in comparison to the
inflammation markers interleukin (IL)-8 in serum and
polymorphonuclear (PMN) elastase in plasma. A total
of 24 consecutive patients, who met the American
College of Chest Physicians/Society of Critical Care
Medicine criteria for septic shock, were enrolled in
this prospective, randomized, double-blind, single-
center trial. The severity of illness at recruitment was
graded using the Acute Physiology and Chronic
Health Evaluation II and the Simplified Acute Physi-
ology Score II scoring systems. Multi-organ dysfunc-
tion syndrome was described by the Sepsis-related
Organ Failure Assessment (SOFA) score. All patients
were prospectively randomized to receive either
stress doses of hydrocortisone or placebo. Hydrocor-
tisone was started in 12 patients with a loading dose
of 100 mg and followed by a continuous infusion of
0.18 mg/kg/h for 6 days. Median S-100B serum levels
of the hydrocortisone group decreased from 0.32
ng/mL at study entry to 0.07 ng/mL 6 days later with-
out significant differences compared to the placebo
group. Initial IL-8 serum levels were significantly high-
er in the hydrocortisone group up to 12 h after study
entry, and significantly decreased from 715 to 17
pg/mL at the end of the observation period. Median
PMN elastase plasma levels were not affected by
hydrocortisone infusion. Patients with initial S-100B
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serum levels)0.50 ng/mL revealed significantly high-
er SOFA scores up to 30 h, IL-8 serum levels up to
12 h, and PMN elastase plasma levels up to 36 h after
study entry than those patients with F0.50 ng/mL.
These effects were independent of the amount of fluid
correction for hemodilution. Starting S-100B, IL-8 and
PMN elastase values of the hydrocortisone group
were within the ranges already known in patients with
out-of-hospital cardiac arrest or severe traumatic
brain injury. Stress doses of hydrocortisone resulted
in a significant reduction in IL-8 serum, but not in S-
100B serum and PMN elastase plasma concentrations
in patients with hyperdynamic septic shock. For the
first time, a similar extent of S-100B increase in serum
of septic patients at the time of diagnosis was shown
as reported for cardiac arrest or severe traumatic
brain injury.
Keywords: cerebral ischemia; hydrocortisone; inflam-
mation; septic shock; S-100B.
Introduction
The endogenous glucocorticoid hydrocortisone plays
a pivotal role in modulation of the immune response
to sepsis (1). Low-dose hydrocortisone infusions may
attenuate this systemic inflammatory response, as
judged by clinical signs and inflammatory markers
(2–4). Two double-blind, single-center trials demon-
strated that stress doses of hydrocortisone reversed
septic shock, as defined by cessation of vasopressor
therapy. The earlier weaning from vasopressor ther-
apy in septic shock was associated with improve-
ments in organ dysfunction and mortality rates (5, 6).
Apart from failure of many vital parenchymal
organs, critical illness myopathy or dysfunction of
peripheral nerves, septic shock may cause serious
brain damage and septic encephalopathy (7–10). Sep-
tic encephalopathy represents a multifocal or diffuse
cerebral malfunction, which may occur in the context
of a systemic infection without direct traumatic af-
fection of the brain (11–14). The prognosis for septic
patients clearly correlates with the presence and
severity of encephalopathy. Mortality in patients with-
out encephalopathy varies between 0% and 26% (11)
and amounts to nearly 50% in patients with severe
symptoms of encephalopathy. Although the severity
of the systemic infection seems to be responsible for
the high mortality rate rather than the encephalopa-
thy itself, an increase in mortality rate was reported
in relation to the Glasgow-Coma-Scale (GCS) score in
50 patients with septic encephalopathy (14). This
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score is still used for the evaluation of neurological
dysfunction and prognosis throughout the course of
multi-organ failure (MOF) (15, 16). However, since
determination of the GCS score in septic shock is
clearly influenced by the use of analgesia sedation
during artificial ventilation, the evaluation of a reliable
biochemical marker, which could supply evidence for
encephalopathy in the initial phase of sepsis and
before the occurrence of clinically leading symptoms,
seems meaningful.
Measurement of the neuroprotein S-100B released
into the circulation was considered as a reliable pro-
cedure in detecting brain damage due to isolated trau-
matic brain injury (17), stroke (18), hemorrhage (19)
or global ischemia (20, 21). Increased S-100B serum
levels have also been observed to correlate with the
duration of cardiopulmonary bypass surgery (22) and
the associated development of neurological compli-
cations (23, 24). S-100B is physiologically localized in
the cytosol or bound to the membranes of astroglial
cells, mostly of the central nervous system (25). If
these cells are damaged, S-100B is rapidly released,
leaking into the cerebrospinal fluid and secondarily
across the blood-brain barrier into the circulation. The
protein is eliminated by the kidney with a biological
half-life between 30 and 113 min (26, 27). Continu-
ously increasing S-100B serum levels after brain in-
jury may reflect both early cellular damage due to
impaired permeability of the blood-brain barrier (24)
and delayed renal elimination.
The objective of our study, which was part of a
double-blind trial, was to analyze the effect of stress
doses of hydrocortisone on circulating S-100B as a
possible measure of neurological dysfunction in
patients during the initial phase of hyperdynamic sep-
tic shock, and to compare these results with the pro-
file of two well-known inflammation parameters
winterleukin-8 (IL-8) and polymorphonuclear (PMN)
elastasex in the circulation.
Materials and methods
Study design and subjects
The study protocol was approved by the institutional Review
Board of the Ludwig-Maximilians-University of Munich. Rel-
atives of the patients were informed regarding the medical
problems, as well as the nature and purpose of the study,
and served as surrogates to determine the judgment of
unconscious patients with respect to participation in the
study. The study was conducted in the multidisciplinary
intensive care unit (ICU) of the Department of Anesthesiol-
ogy Munich-Grosshadern in the university hospital.
Patients suffering from septic shock were prospectively
enrolled if they were on vasopressor support and met the
criteria for septic shock proposed by the members of the
American College of Chest Physicians (ACCP)/Society of Crit-
ical Care Medicine (SCCM) Consensus Conference Commit-
tee (28): documented infection or positive blood culture; at
least two symptoms of the systemic inflammatory response
syndrome, such as fever (body temperature)388C) or hypo-
thermia (body temperature -368C), tachycardia ()90 beats/
min), tachypnea ()20 breaths/min) or hyperventilation
wPaCO2 -32 torr (4.33 kPa)x, and abnormal white blood cell
counts w)12,000 cells/mm3 or -4,000 cells/mm3 or imma-
ture neutrophils (bands )10%)x evidence of organ dys-
function or hypoperfusion abnormality; and persistent
sepsis-induced hypotension despite adequate fluid resusci-
tation or the use of inotropic or vasopressor support.
Fluid resuscitation was considered to be adequate when
the pulmonary capillary wedge pressure (PCWP) reached
values between 12 and 15 mm Hg. Referring to the SCCM
guidelines, only patients on vasopressor support and with
high-output circulatory failure defined by a cardiac index (CI)
)4.0 L/min/m2 (in patients )55 years, )3.5 L/min/m2 due to
reduced cardiac output with age) were randomized to the
treatment groups. The hypercirculatory state had to be pres-
ent without the use of positive inotropic agents such as
dobutamine, dopexamine or epinephrine. Patients who were
treated with vasopressors for )72 h or with glucocorticoids
were not included. The definition of the target population
was based on data from a pilot study (29); the study design
and patient treatment routine have already been described
(5).
Vasopressor therapy was titrated to achieve a mean arte-
rial pressure (MAP) of )70 mm Hg. If dopamine exceeded a
dose of 10 mg/kg/min, norepinephrine combined with dopa-
mine in low dose (2–4 mg/kg/min) was the proposed drug
option. After randomization, however, the attending physi-
cians were free to use additional catecholamines such as epi-
nephrine, dobutamine, or dopexamine. When septic shock
reversed, norepinephrine or epinephrine was tapered off in
steps of 0.02–0.03 mg/kg/min (5).
Infections were diagnosed according to clinical and micro-
biological criteria. Suspected infection at the time of enrol-
ment was proven by clinical or microbiological examination.
Bacterial infections were treated with selective antibiotic reg-
imens, with preference given to third-generation cephalo-
sporins, the carbapenem imipenem-cilastin, or the quinolone
ciprofloxacin. Bacterial and fungal cultures (respiratory
secretions, urine, peritoneal fluid, and wound swabs) were
routinely assayed on fixed days twice each week. In addition,
swabs of the peritoneum were taken from each quadrant of
the abdomen in cases of surgery. In cases of new or unex-
plained fever ()38.58C), two blood cultures were taken by
intravenous puncture, and all venous and arterial catheters
were changed. The tips of all catheters were examined for
colonies of bacteria or fungi. Bronchoscopy with bronchoal-
veolar lavage and protected-brush specimens was carried
out in cases of new pulmonary infiltrates indicated on the
chest radiograph. Selective decontamination of the naso-
oropharynx and the digestive tract was performed through-
out the period spent in the ICU using a regimen of polymyxin
B (50 mg every 6 h) and gentamicin (80 mg every 6 h) dis-
solved in 10 mL of 0.9% saline. A 1-mL aliquot of this solu-
tion was instilled into each nostril, 3 mL into the oropharynx,
and 5 mL via a nasogastric tube into the stomach (5).
The severity of illness at the time of enrolment was deter-
mined using the Acute Physiology and Chronic Health Eval-
uation (APACHE) II and III, and Simplified Acute Physiology
scoring (SAPS) systems. The primary study endpoint was
the time to shock reversal, as defined by cessation of vaso-
pressor support. Secondary endpoints were hyperdynamic
alteration, multiple-organ dysfunction syndrome, systemic
inflammatory response, and evolution of coagulation disor-
ders (5).
During controlled ventilation and treatment with antibiot-
ics, infusions, and systemic vasopressor support in the ICU,
anesthesia aimed at a constant GCS score of 3 points was
achieved by titration of midazolam and fentanyl. Therefore,
the neurological investigation had to be limited to the exam-
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ination of reflexes. When the sedative drugs were reduced,
the actual GCS score was recorded, using the grading pro-
posed for patients on mechanical ventilation (30). The Sep-
sis-related Organ Failure Assessment (SOFA) score, which
was published in 1996 (31), was added to the study protocol
by amendment and retrospectively calculated from the raw
data.
Interventions
A total of 24 patients were prospectively randomized to
receive infusions of either stress doses of hydrocortisone
(ns12) or placebo (ns12). Hydrocortisone administration
was started with a loading dose of 100 mg, administered
intravenously in 30 min, followed by continuous infusion of
0.18 mg/kg/h. According to the SCCM guidelines, either con-
tinuous infusion of 200–300 mg hydrocortisone/day for
7 days with subsequent dose reduction, or low-dose appli-
cation of 50–75 mg hydrocortisone four times a day is rec-
ommended for the management of patients with septic
shock (32). After reversal of septic shock (defined as dopa-
mine doses of -6 mg/kg/min or cessation of norepinephrine/
epinephrine infusion) the dose of hydrocortisone was
reduced to 0.08 mg/kg/h. This dose was kept constant for
6 days. As soon as the underlying infection had been trea-
ted successfully or the sodium serum concentrations had
increased to )155 mmol/L, the hydrocortisone infusion was
tapered off in steps of 24 mg/day. Physiological saline solu-
tion was used as placebo. To conduct the study in a double-
blind manner, the study drugs were prepared by research
assistants at our institution, who were not involved in the
study or in the clinical care of the patients. Study drug prep-
aration has been already described (5).
For continuous venovenous hemofiltration (CVVH; ns10)
blood was taken from the subclavian, internal jugular, or
femoral vein, and a blood pump was used to perfuse the
filtration membrane. The dialysate compartment of the
membrane unit was under negative pressure relative to the
blood compartment, which permitted hydraulic ultrafiltration
of excess fluid across the membrane. Dialyzed blood was
returned to the patient through tubing with an air embolus
protector. To prevent clotting in the extracorporeal circuit,
heparin was given to produce full systemic anticoagulation
(whole blood clotting time )30 min). Anticoagulation was
permanently monitored, and the heparin dose was subse-
quently individualized.
Blood sampling and biochemical measurements
The first blood samples were taken at study entry in the ICU
wpoint of measurement (PM)1x. Subsequently, blood samples
were drawn every 6 h (PM2–9) during the next 2 days, and
once a day throughout the following 4 days (PM10–13). All
specimens were converted to serum or citrated plasma, cen-
trifuged with 3000 U/min for 10 min at room temperature,
and frozen in aliquots at y708C until batch evaluation.
S-100B serum levels were analyzed by means of an immu-
noluminometric assay (LIAMAT Sangtec100; Byk-Sangtec
Diagnostica, Dietzenbach, Germany) with a lower detection
limit of 0.02 ng/mL and a cut-off level of -0.12 ng/mL for
normal values. IL-8 serum values were determined using a
quantitative ELISA (IL-8 Milenia; Milenia Biotec, Bad Nau-
heim, Germany) with a detection limit of 0.5 pg/mL and a
normal range of 0–30 pg/mL. Plasma levels of PMN elastase
complexed with a1-proteinase inhibitor were quantified by
means of a specific two-site ELISA (PMN Elastase Milenia;
Milenia Biotec; normal values 19–78 ng/mL).
Total serum protein concentrations were measured with a
specific microprotein assay kit (Micro BCA Protein Assay;
Pierce, Rockford, IL, USA) in order to avoid interferences
with possible hemodilution. Due to logistic reasons (limited
sample size) we had to use the BCA assay instead of the
Biuret total protein assay. In addition, the C-reactive protein
(CRP) serum levels (mg/dL), as well as the creatinine serum
levels (mg/dL) and fluid balance (mL) per 24 h were calcu-
lated to identify the amount of fluid correction for
hemodilution.
Statistical analysis
All demographic and biochemical data are presented as
median and interquartile range (IQR; 25th–75th percentile).
Group differences at each point of measurement were
accomplished by means of a Mann-Whitney U-test or Wil-
coxon test due to non-normal distribution of the data. The
Kaplan-Meier method was used to determine the probability
of being on vasopressor therapy over time. The failure times
until cessation of vasopressor therapy were compared using
a generalized Wilcoxon (Breslow) test.
The entire study group was differentiated into subgroups
1 ()0.50 ng/mL) and 2 (F0.50 ng/mL) with respect to S-100B
levels at study entry. Biochemical data for septic patients
were compared to those reported for patients with out-of-
hospital cardiac arrest or isolated severe traumatic brain
injury (GCS score F8 points), and healthy volunteerswithout
a history of brain or cardiac damage (17, 21, 33). Blood sam-
pling of the control groups was carried out after informed
consent. The statistical analysis was performed using SPSS
version 12.0 (SPSS GmbH Software, Munich, Germany), and
a two-tailed p-value of -0.05 was considered to be
significant.
Results
Demographic and clinical characteristics of the
study groups
A total of 12 patients were assigned each to the ther-
apy group receiving stress doses of hydrocortisone
(H) and to the placebo (P) group, respectively (5). The
characteristics of both patient groups did not differ
according to demographic data, severity of the illness
and the degree of organ dysfunction (Table 1). In addi-
tion, no significant differences occurred concerning
CVVH application, length of artificial ventilation and
survival rate after 28 days between the groups.
Shock reversal was achieved in 11 of the 12 patients
treated with hydrocortisone vs. 9 of the 12 patients
treated with placebo. The median time of vasopressor
support in group H w2 days (IQR 1–6)x was signifi-
cantly reduced compared to group P w7 days (3–19);
Figure 1x. Specific analysis revealed significant
increases in terms of mean arterial pressure and sys-
temic vascular resistance, and showed a trend to ear-
lier resolution of the organ dysfunction syndrome in
group H (5).
No differences were evident between the groups
regarding the type and anatomical site of the under-
lying infection. The primary cause of septic shock was
peritonitis in 9 patients (4 in group H, 5 in group P)
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Table 1 Characteristics of septic shock patients randomized into hydrocortisone (ns12) and placebo (ns12) groups.
Characteristic Group p
Hydrocortisone Placebo
(ns12) (ns12)
Age, years 41 (30–65) 54 (47–57) 0.410
Male, % 58 50 0.755
APACHE II score, points 25 (20–28) 28 (18–32) 0.590
APACHE III score, points 85 (71–104) 85 (53–112) 0.671
SAPS II score, points 53 (46–60) 48 (42–76) 0.630
CVVH, % 42 42 1.000
Length of ventilation, days 16 (12–24) 21 (8–38) 0.755
Mortality rate, % 25 42 0.514
Primary cause of sepsis
Peritonitis, % 33 42 0.466
Pneumonia, % 58 50 0.755
Baseline values
S-100B, ng/mL 0.32 (0.19–3.60) 0.41 (0.18–0.70) 0.062
IL-8, pg/mL 715 (156–6275) 94 (68–948) -0.010*
PMN elastase, ng/mL 637 (496–1680) 522 (173–674) 0.058
CRP, mg/dL 25 (22–33) 19 (13–36) 0.148
Creatinine, mg/dL 1.2 (0.8–2.3) 1.0 (0.7–1.8) 0.563
Fluid balance, mL 2200 (25–4188) 2500 (580–4025 0.870
Age, scores and days of ventilation are presented as median and interquartile range (25%–75% percentile). *Significant dif-
ference between groups in the Mann-Whitney U-test.
Figure 1 Kaplan-Meier curves showing the probability of
being on vasopressor therapy during the course of the study.
Comparisons between the time distribution of both treat-
ment groups were performed by means of generalized Wil-
coxon (Breslow) test; ps0.006.
and pneumonia in 13 patients (7 in group H, 6 in
group P). In all nine subjects, peritonitis required at
least one surgical intervention, which was applied in
a timely manner, in most cases immediately after
study entry. One patient each suffered from menin-
gitis and severe soft tissue infection, respectively. The
initial antibiotic treatment was inadequate in seven
patients (3 in group H, 4 in group P) and was correct-
ed according to the results of the microbiological
examinations.
S-100B/IL-8 serum and PMN elastase plasma levels
after randomization in hydrocortisone or placebo
group
Baseline median S-100B, IL-8, and PMN elastase lev-
els were considerably elevated for both groups com-
pared to values for healthy individuals (Figure 2).
After hydrocortisone infusion, only median serum
concentrations of IL-8 decreased significantly from
715 pg/mL (156–6275 pg/mL) to 17 pg/mL (12–32
pg/mL) at the end of the observation period, reaching
the normal range by 18 h after study entry w28 pg/mL
(16–121 pg/mL); PM4x. In contrast, S-100B serum and
PMN elastase plasma levels in group H were not sig-
nificantly affected over time (Figure 2). Similarly,
serum concentrations of S-100B and IL-8, as well as
plasma concentrations of PMN elastase in group P did
not significantly decrease during the observation
period.
Median S-100B serum levels in group H decreased
from 0.32 ng/mL (0.19–3.60 ng/mL) at study entry to
0.07 ng/mL (0.04–0.32 ng/mL) 6 days later, without
significant differences compared to group P. Only S-
100B levels at PM3 (12 h after study entry) at 0.87
ng/mL (0.14–2.63 ng/mL) were significantly higher in
group H compared to 0.37 ng/mL (0.14–0.77 ng/mL)
in group P (Figure 2). Initial median IL-8 serum levels
in group H were significantly higher compared to
group P only from study entry w715 pg/mL
(156–6275 pg/mL)x until 12 h later w49 pg/mL
(33–428 pg/mL)x. Median PMN elastase plasma levels
did not differ between the groups with time, although
PMN elastase values from PM1 (study entry) to PM4
(18 h after study entry) were slightly higher in group
H than in group P (Figure 2).
Median CRP serum values in both groups were sig-
nificantly elevated compared to those in healthy
individuals. Only median CRP levels in group H sig-
nificantly decreased from 25 (22–33) to 14 (8–20)
mg/dL 3 days after study entry (PM10) and to 7 (2–13)
mg/dL at the end of the observation period, but did
not reach the normal range (Figure 2). Although CRP
values in group H were slightly higher from PM1
(study entry) to PM8 (42 h after study entry), median
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 11:21
Mussack et al.: S-100B under hydrocortisone in septic shock 263
Article in press - uncorrected proof
Figure 2 Serum S-100B, IL-8, and plasma PMN elastase levels, as well as serum CRP levels and fluid balance within the first
6 days of septic shock. Patients were randomized in the hydrocortisone group (ns12; ●; data are given as line and scatter
plots presenting median and 75th percentile) or the placebo group (ns12; ; data are given as line and scatter plots presenting
median and 25th percentile). The upper normal value amounts to 0.12 ng/mL for S-100B, to 30 pg/mL for IL-8, to 78 ng/mL
for PMN elastase and to 0.5 mg/dL for CRP. The first blood samples were taken at study entry at the ICU. Subsequent blood
samples were drawn every 6 h during the next 2 days, and once a day throughout the following 4 days. qp-0.05 represents
significant group differences between the two randomized groups. *p-0.05 shows significant differences compared to the
baseline levels at study entry.
serum CRP and fluid balance (Figure 2), as well as
baseline creatinine levels, did not differ between the
groups (Table 1).
SOFA score, IL-8 serum and PMN elastase plasma
levels depending on the initial S-100B serum levels
As shown in Table 2, patients in subgroup 1 (ns8;
initial S-100B serum level )0.50 ng/mL) showed no
statistical differences concerning age, gender, SAPS
II score, or administration of hydrocortisone when
compared to those in subgroup 2 (ns16; initial S-
100B serum level F0.50 ng/mL). In contrast, the
APACHE II and APACHE III score, CVVH application,
days required for artificial ventilation, and mortality
rate after 28 days were significantly higher in sub-
group 1 patients (Table 2).
The median S-100B serum levels in subgroup 1
were always significantly higher than in subgroup 2
(Figure 3). Interestingly, the initial, highly elevated
S-100B values in subgroup 1 of 2.60 ng/mL
(1.52–5.89 ng/mL) were within the data ranges recent-
ly demonstrated for patients with out-of-hospital car-
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Table 2 Characteristics of septic shock patients with pathologically elevated initial S-100B serum levels )0.50 ng/mL (sub-
group 1) and F0.50 ng/mL (subgroup 2).
Characteristic Subgroup p
1 (ns8) 2 (ns16)
Age, years 41 (30–52) 55 (33–66) 0.070
Male, % 50 50 1.000
APACHE II score, points 28 (25–29) 22 (18–27) 0.016*
APACHE III score, points 98 (74–141) 75 (54–87) 0.029*
SAPS II score, points 65 (46–89) 48 (42–54) 0.070
CVVH, % 75 19 0.020*
Length of ventilation, days 24 (14–32) 14 (6–20) 0.038*
Hydrocortisone, % 63 44 0.482
Mortality rate, % 50 25 0.046*
Age, scores and days of ventilation are presented as median and interquartile range (25th–75th percentile). *Significant
difference between groups in the Mann-Whitney U-test.
diac arrest or severe traumatic brain injury (21, 33).
Furthermore, median S-100B serum levels in sub-
group 2 decreased to 0.05 ng/mL (0.02–0.18 ng/mL) at
PM13, and were still elevated compared to the value
for healthy controls of 0.04 ng/mL (0.01–0.08 ng/mL)
(17).
Patients in subgroup 1 showed higher median
SOFA scores than those in subgroup 2 during the
observation period, but the differences were signifi-
cant only from PM1 to PM6 (Figure 3).
Subgroup 1 showed only significantly higher medi-
an IL-8 serum levels from PM1 to PM3 compared to
subgroup 2. From PM4 to the end of the observation
period, median IL-8 serum levels were similar in both
subgroups, and ranged within standard values by
24 h after study entry (PM5). Highly increased PMN
elastase values declined in both subgroups with time,
but remained clearly elevated above the normal range
at the end of the observation period. However,
patients in subgroup 1 showed significant differences
in PMN elastase plasma levels compared to subgroup
2 only from study entry (PM1) to 36 h later (PM7).
Median CRP serum values remained clearly elevat-
ed in both subgroups during the entire observation
period. Only CRP levels in subgroup 2 significantly
decreased from 25 mg/dL (18–41 mg/dL; PM1) to
14 mg/dL (9–21 mg/dL) 3 days after study entry
(PM10) and to 9 mg/dL (5–13 mg/dL) 5 days after
study entry (PM12). However, median serum CRP and
fluid balance did not differ between the subgroups
(Figure 3).
Discussion
Clinical sequelae of hyperdynamic septic shock are
organ dysfunction, such as mental disorders, dissem-
inated intravascular coagulation, acute lung injury,
renal failure, acute hepatic dysfunction, and cardio-
vascular dysfunction (31). The physiological function
of hypercortisolemia associated with stress is to mod-
ulate the normal defense mechanisms, thus protect-
ing the host from overactivation of inflammatory
reactions (34). Cortisol interacts with the immune sys-
tem at several levels, exerting suppressive and per-
missive effects. In a dose-dependent manner,
corticosteroids inhibit proinflammatory cytokine syn-
thesis and cellular immunity (35).
Since we observed mineralocorticoid effects of
hydrocortisone infusion by measuring serum sodium
and potassium concentrations, mineralocorticoids
were not added to the treatment (5). Stress levels of
cortisol increase sodium retention and produce
hypertension in healthy humans. This effect is medi-
ated by Type I and Type IV corticoid receptors (36).
The increase in sodium concentrations in the hydro-
cortisone-treated group in this study suggests that
mineralocorticoid effects of hydrocortisone contribute
to improved vasopressor response (5).
One major finding of this study is that hydrocorti-
sone administered in stress doses selectively reduced
circulating IL-8 serum levels, but not S-100B serum
and PMN elastase plasma levels in patients with
hyperdynamic septic shock. This effect is obviously
independent of the extent of fluid correction for
hemodilution. Cytokines are peptides that primarily
regulate the interaction and communication of cells
of the immune system. In cases of infection, cytokines
initiate the systemic inflammatory response by inter-
acting with specific receptors on inflammatory target
cells (1). IL-8, which is predominantly discharged
from activated macrophages and endothelial cells
into the circulation, represents an important chemo-
attractant for neutrophil granulocytes. During the
whole-body inflammation in septic shock, these gran-
ulocytes release destructive superoxide anions and
lysosomal enzymes such as PMN elastase upon acti-
vation (37–40). Since significant differences between
patients receiving hydrocortisone or placebo were
shown only for IL-8 serum concentrations compared
to baseline levels, hydrocortisone does not seem to
have a substantial influence on the release of PMN
elastase in hyperdynamic septic shock.
However, the clinical data from this therapy study
agree very well with results from other reports (2, 6).
A significant improvement in the hemodynamic situ-
ation, i.e., an increase in mean arterial pressure and
systemic vascular resistance, associated with a clear
reduction of the need for catecholamines could be
observed after application of stress doses of hydro-
cortisone instead of placebo (Figure 1). The reversal
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Figure 3 SOFA score, serum S-100B, IL-8, CRP, and plasma PMN elastase levels, as well as fluid balance within the first
6 days of septic shock. Patients were stratified in groups with an initial S-100B serum level )0.50 ng/mL (ns8; ●; data are
given as line and scatter plots presenting median and 75th percentile) or F0.50 ng/mL (ns16; ; data are given as line and
scatter plots presenting median and 25th percentile). qp-0.05 represents significant group differences between the two
randomized groups.
of septic shock in the hydrocortisone group occurred
more quickly than in the placebo group (2, 5, 6). How-
ever, during the observation period of 6 days, no sig-
nificant difference concerning a decrease in the
originally highly elevated S-100B serum levels were
apparent when using hydrocortisone compared to
placebo.
The exact mechanisms that lead to similarly high
S-100B serum concentrations, particularly in the ini-
tial phase of septic shock, as in patients with severe
head injury are still unclear. Neuronal cells, as well as
damaged fat and muscle cells, must be considered as
possible sources for the release of S-100B (41–43).
Interestingly, patients with pathologically elevated ini-
tial S-100B serum levels of )0.50 ng/mL showed sig-
nificantly higher median SOFA scores up to 30 h after
study entry than those patients with initial levels
F0.50 ng/mL. Moreover, individuals with clearly
raised S-100B levels exhibited higher PMN elastase
plasma levels until 36 h, whereas their IL-8 serum lev-
els were elevated only up to 12 h after study entry.
Although impairment of astroglial cells, possibly lead-
ing to prolonged neurological dysfunction, cannot be
excluded as the primary origin of S-100B in the cir-
culation, the systemic inflammatory process and
peripheral tissue damage also have to be taken into
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account as an additional cause for the different
release pattern of S-100B protein (25, 41, 44).
In critically ill patients with septic syndrome, dis-
turbance of the neurological functions can arise from
a multitude of origins. Patients may have head inju-
ries due to accidental trauma or can be intoxicated.
Furthermore, they may suffer from prolonged shock
in the case of severe systemic infection and may need
to be resuscitated under sedation analgesia because
of vasogenic reactions, myocardial dysfunction or
coagulation disturbances (45). Particularly in the early
phase of the disease, septic encephalopathy is quite
difficult to diagnose in patients with concomitant dis-
turbance of kidney or liver function, with metabolic
collapse or with endocrine abnormalities due to the
similarity to cerebral dysfunctions of other origins.
The early form of septic encephalopathy, which
may not yet be accompanied by MOF, but probably
only by the release of pro- and anti-inflammatory
cytokines and their cytotoxic effects, is different from
the late form, which is usually combined with MOF,
hypotension, and other systemic symptoms. Septic
encephalopathy is clinically characterized by distur-
bances of concentration and disorientation, as well as
by delirium and coma in heavy cases. Encephalopa-
thy may precede the leading symptoms of sepsis, and
may thus be of special diagnostic value as a possible
early marker of subsequent organ system failures (11,
12, 46). Radiological examinations, i.e., cerebral com-
puted tomography (CCT), do not usually show any
significant changes. Clinical evaluation can be
achieved by means of electroencephalography (EEG)
or the GCS score before sedation analgesia and intu-
bation are applied.
The GCS score is frequently applied for the exami-
nation of cerebral dysfunctions. It correlates very well
with the neurological long-term result in patients with
severe head injuries, and can also be used for the
evaluation of neurological dysfunctions in the long-
term course of patients with MOF (15, 16). Eidelman
et al. (14) reported increased mortality in 50 patients
with septic encephalopathy in relation to the GCS
score (16% at 15 points and 63% between 3 and 8
points). However, the clinical experience shows that
the GCS score cannot always be estimated meaning-
fully in ICU patients with septic shock (30). Indeed,
nearly all patients in our prospective randomized ther-
apy study (5) were already sedated and ventilated for
several days, and exhibited a continuous GCS score
of 3 points when finally fulfilling the study entry cri-
teria. Therefore, a valid neurological evaluation in the
clinical process was practically impossible and the
clinical diagnosis of septic encephalopathy would
only have been possible by means of EEG. Yet, EEG
was not typically applied due to the study design, for
which measurements of S-100B serum levels were
primarily not conceived (5).
In this situation, the introduction of a specific bio-
chemical brain marker seemed to us to be of great
interest for the retrospective diagnosis and predic-
tion of septic encephalopathy in the long term.
According to a recent study, the neuroprotein S-100B
is expressed and released into the circulation not only
in ischemic brain tissue damage after stroke or trau-
matic brain injury, but also during brain inflammation
(47). Whether high local extracellular concentrations
of S-100B have detrimental effects, such as the
enhancement of apoptotic cell death, is still under
debate (44). Therefore, we decided to evaluate S-100B
serum levels in our patients with septic shock, whose
serum samples were collected in the context of a pro-
spective randomized study examining the effective-
ness of hydrocortisone (1, 4, 5).
Although our data reveal for the first time the sim-
ilar extent of systemic S-100B release after septic
shock as after out-of-hospital cardiac arrest or trau-
matic brain injury, the main limitation of this random-
ized controlled study is the small number of patients.
From this it follows that the study may be under-
powered with respect to the ability to identify any
significant differences concerning age, days of venti-
lation or mortality rate.
Conclusions
Hypercortisolemia induced by the infusion of stress
doses of hydrocortisone differentially regulates the
response of the neuroprotein S-100B and the inflam-
mation markers IL-8 and PMN elastase in patients
with hyperdynamic septic shock. In a randomized
double-blind trial, we observed a significant reduction
in IL-8 serum, but not in S-100B serum and PMN elas-
tase plasma concentrations with time. For the first
time, a similar extent of S-100B increase in serum of
patients with septic shock at the time of primary diag-
nosis was shown as reported for out-of-hospital car-
diac arrest or severe head injury. Although clinically
relevant methods for judging brain damage in our
septic shock patients are missing due to the study
design, our data give clear hints for further prospec-
tive studies on S-100B serum levels in septic patients.
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